Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Poniard Given SFDA Approval for Phase III Cancer Trial

publication date: Mar 1, 2011
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Poniard Pharmaceuticals has been granted SFDA approval to conduct two Phase III trials in China of its lead drug candidate, picoplatin, as a treatment for second-line small cell lung cancer (SCLC) and second-line ovarian cancer. Poniard, which is a US company without any China operations, said the approval would increase the drug’s value to prospective development partners. More details....

Stock Symbol: (NSDQ: PARD)



Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China


>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners